LEAD 2: demonstrating liraglutide as an add-on to an OADA 26-week, double-blind, placebo- and active-controlled, parallel-group multicentre study showing HbA1c reductions. The study compared the efficacy and safety of liraglutide, metformin and placebo, all in combination with SU, in type 2 diabetes.
Added: 20/12/11
Related Tags: oral antidiabetic, GLP-1, liraglutide